Technetate(3-)-99Tc, (N-(4-(((2-Amino-1,4-Dihydro-4-Oxo-6-Pteridinyl)Methyl)Amino)Benzoyl)-D-.Gamma.-Glutamyl-(2S)-2-(Amino-.Kappa.N)-.Beta.-Alanyl-L-.Alpha.-Aspartyl-.Kappa.N-L-Cysteinato(6-)-.Kappa.N,.Kappa.S)Oxo-, Hydrogen (1:3), (Sp-5-24)-

Crohn Disease

Mayo ClinicSmall moleculePhase 2Dormant

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

10 Active assets in the Crohn Disease cohort.

Asset / Sponsor	Phase	Rating
Dexasone University of Saskatchewan	Phase 4	BB
Marcaine Cedars-Sinai Medical Center	Phase 4	BB
Epinephrine Cedars-Sinai Medical Center	Phase 4	BB
Prucalopride University of British Columbia	Phase 4	BB
Hextend Corewell Health West	Phase 3	BB

View all 20 →

Same molecule, other indications

Technetate(3-)-99Tc, (N-(4-(((2-Amino-1,4-Dihydro-4-Oxo-6-Pteridinyl)Methyl)Amino)Benzoyl)-D-.Gamma.-Glutamyl-(2S)-2-(Amino-.Kappa.N)-.Beta.-Alanyl-L-.Alpha.-Aspartyl-.Kappa.N-L-Cysteinato(6-)-.Kappa.N,.Kappa.S)Oxo-, Hydrogen (1:3), (Sp-5-24)- is also rated in:

rheumatoid arthritisDormant

Indicative · Phase 2

57 / 100

View asset →

osteoarthritisDormant

Indicative · Phase 2

57 / 100

View asset →

systemic lupus erythematosusDormant

Indicative · Phase 2

57 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →